Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0W8BP
|
|||
Former ID |
DNC008895
|
|||
Drug Name |
C[Cpa19-Lys26][Gly8]GLP-1(7-37)-NH2
|
|||
Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
Structure |
Download2D MOL
|
|||
Formula |
C151H225N41O46
|
|||
Canonical SMILES |
CCC(C)C(C(=O)NC(C)C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCCN)C(=O)NCC(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CCC(=O)O)NC(=O)C4CCCCNC(=O)C5=CC=C(CC(C(=O)NC(C(=O)NC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)N4)C)C)CCC(=O)N)CCC(=O)O)CC(C)C)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC6=CC=CC=C6)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)CNC(=O)C(CC7=CN=CN7)N)C=C5
|
|||
InChI |
1S/C151H225N41O46/c1-16-77(10)121(148(236)170-80(13)126(214)178-104(59-87-62-161-91-35-24-23-34-89(87)91)138(226)180-100(55-74(4)5)139(227)189-119(75(6)7)146(234)177-93(36-25-27-51-152)130(218)164-66-112(201)171-92(38-29-53-160-151(156)157)129(217)162-64-110(155)199)191-140(228)102(56-83-30-19-17-20-31-83)181-135(223)98(46-50-117(208)209)176-134(222)94-37-26-28-52-159-127(215)86-41-39-85(40-42-86)58-101(137(225)179-99(54-73(2)3)136(224)175-96(45-49-116(206)207)132(220)165-67-113(202)173-97(43-47-109(154)198)133(221)169-78(11)124(212)168-79(12)125(213)174-94)182-143(231)106(69-193)185-145(233)108(71-195)186-147(235)120(76(8)9)190-142(230)105(61-118(210)211)183-144(232)107(70-194)187-150(238)123(82(15)197)192-141(229)103(57-84-32-21-18-22-33-84)184-149(237)122(81(14)196)188-114(203)68-166-131(219)95(44-48-115(204)205)172-111(200)65-163-128(216)90(153)60-88-63-158-72-167-88/h17-24,30-35,39-42,62-63,72-82,90,92-108,119-123,161,193-197H,16,25-29,36-38,43-61,64-71,152-153H2,1-15H3,(H2,154,198)(H2,155,199)(H,158,167)(H,159,215)(H,162,217)(H,163,216)(H,164,218)(H,165,220)(H,166,219)(H,168,212)(H,169,221)(H,170,236)(H,171,201)(H,172,200)(H,173,202)(H,174,213)(H,175,224)(H,176,222)(H,177,234)(H,178,214)(H,179,225)(H,180,226)(H,181,223)(H,182,231)(H,183,232)(H,184,237)(H,185,233)(H,186,235)(H,187,238)(H,188,203)(H,189,227)(H,190,230)(H,191,228)(H,192,229)(H,204,205)(H,206,207)(H,208,209)(H,210,211)(H4,156,157,160)/t77-,78-,79-,80-,81+,82+,90-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,107-,108-,119-,120-,121-,122-,123-/m0/s1
|
|||
InChIKey |
NBZJWICSDFBTTN-RHBBJNDVSA-N
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Glucagon-like peptide 1 receptor (GLP1R) | Target Info | Inhibitor | [1] |
KEGG Pathway | cAMP signaling pathway | |||
Neuroactive ligand-receptor interaction | ||||
Insulin secretion | ||||
Reactome | Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | |||
G alpha (s) signalling events | ||||
Glucagon-type ligand receptors | ||||
WikiPathways | GPCRs, Class B Secretin-like | |||
Integration of energy metabolism | ||||
GPCR ligand binding | ||||
GPCR downstream signaling |
References | Top | |||
---|---|---|---|---|
REF 1 | Design and synthesis of conformationally constrained glucagon-like peptide-1 derivatives with increased plasma stability and prolonged in vivo acti... J Med Chem. 2008 May 8;51(9):2758-65. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.